Navigation Links
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
Date:6/11/2008

- RECIST-defined objective response supports expansion of Simon 2-Stage

designed trial -

BRANFORD, Conn., June 11 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Phase II Trial evaluating CR011-vcMMAE for the treatment of patients with unresectable Stage III or Stage IV melanoma has met the efficacy criteria for advancement to the second stage of enrollment. Of the first six evaluable patients in this Phase II trial one patient has had a confirmed objective response, as measured by RECIST criteria. As part of the Simon 2-Stage design the trial will now expand to enroll a total of 32 patients.

"We are very encouraged by the emerging clinical efficacy of CR011-vcMMAE. We believe that this objective response confirms the initial activity observed in the Phase I trial, the results of which were reported earlier this month at ASCO," commented Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen Corporation. "This trial is enrolling well, and we expect the data to quickly mature allowing us to provide further updates from the study later in the second half of this year."

Dr. Ronit Simantov, Vice President and Chief Medical Officer commented, "There remains a substantial unmet need for patients with advanced melanoma. As we continue to evaluate CR011-vcMMAE 1.88 mg/kg given once every three weeks in this ongoing Phase II trial, we are also looking to further optimize the activity of CR011-vcMMAE by actively exploring alternative dosing schedules including more frequent intravenous administration of this novel agent."

This ongoing open-label, multi-center Phase II study e
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014 A victim of medical ... doctor with a history of alcohol abuse, a ... Yes on Prop 46 today, highlighting how Prop 46 will ... alcohol testing. The ad pictures a doctor ... "911-Report To ER."  Proposition 46 will enact the first law ...
(Date:10/17/2014)... , Oct. 17, 2014 The ... Medical Technology Policy: The Green Park ... FDA, public and private payers, medical device and ... and other experts January 12, 2015 at its ... value of weight loss treatments.  Participants will discuss ...
(Date:10/17/2014)... 2014  UBM Medica US announces that Endocrinology ... other clinicians who treat patients with type 2 ... use of insulin .  Nearly all ... therapy – daily injections of one or more ... the function of pancreatic beta cells. Insulin is a ...
Breaking Medicine Technology:Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3
... NATICK, Mass., March 29, 2011 Boston Scientific Corporation ... trial news and events schedule at the 60th Annual ... April 2-5, 2011 in New Orleans. "Twelve-month ... important data on our next-generation PROMUS Element™ Everolimus-Eluting Platinum ...
... 2011 Tris Pharma, Inc., a specialty pharmaceutical company, ... Iron product line.  Since the 2007 launch ... of pediatricians, pediatric nurses and mothers.  When the previous ... different direction, availability of MyKidz Iron™ became limited, but ...
Cached Medicine Technology:Boston Scientific Announces Its ACC 2011 Schedule 2Boston Scientific Announces Its ACC 2011 Schedule 3Boston Scientific Announces Its ACC 2011 Schedule 4Boston Scientific Announces Its ACC 2011 Schedule 5Boston Scientific Announces Its ACC 2011 Schedule 6Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements 2Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements 3
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute ... to repair a damaged mitral valve as the heart ... developed by Abbott Vascular , is designed to ... condition in which the heart’s mitral valve leaflets fail ... the heart’s left ventricle into the left atrium. The ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 T.E.N., ... relationship-marketing firm, announced today that William H. Murray, ... the 2014 ISE® Luminary Leadership Award winner. Presented ... achievements of an outstanding leader and industry practitioner ... contributions in advancing the information security industry. , ...
(Date:10/20/2014)... WA (PRWEB) October 20, 2014 My ... workflow management software application. The new module enables ... patients receive full life-cycle quality care. , This application ... others within their practice, attach a to-do item to ... fit, and even set up reoccurring reminders for follow-ups. ...
(Date:10/20/2014)... Rockynol Retirement Community broke ground on ... $11 million project will include the latest in Assisted ... full-service restaurant style dining. , “We are excited to ... Living apartments,” said Kara Hanzie, Rockynol Executive Director during ... care and this investment is proof of our commitment.” ...
(Date:10/20/2014)... Final Cut Pro X Plugin developers from ... theme for FCPX filmmakers . , “Fun, cool, and ... Citrus theme” Says Christina Austin, CEO of Pixel Film Studios. ... , Citrus comes with all the tools needed for a ... transitions for added style, a title screen for an introduction, ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2
... Smith III, O.D., dean of the College of Optometry at ... his work in slowing the progression of nearsightedness in children. ... chair, accepted the Donald Korb Award for Excellence at a ... of the American Optometric Association (AOA). The Korb ...
... Many members of low-income families are not getting proper nutrition ... the families, eating patterns and the nutritional value of their ... the 100 families, who were newly enrolled in the Nebraska ... vital nutrients, including vitamins A and C, protein, calcium and ...
... June 28, 2011A chemical produced by the same cells that ... 1 diabetes in mice, researchers at St. Michael,s Hospital have ... is characterized by the immune system,s destruction of the beta ... a result, the body makes little or no insulin. ...
... new insight into the brain processes that cause the following ... in the center of the image in this short video ... of the University of Rochester) appears to be expanding. But ... he is growing because our brains have adapted to the ...
... identified specific resistance mutations for two classes of p7 ... clinical trials combined with current standard of care. Study ... potential components of future HCV-specific therapies and are available ... journal published by Wiley-Blackwell on behalf of the American ...
... (HealthDay News) -- A flexible work schedule helps employers retain ... birth, according to a new study. "When confronted by ... moms with alternatives for meeting those demands while caring for ... their work environment and adapt, work-related stress is less likely ...
Cached Medicine News:Health News:Work to slow progression of nearsightedness in children wins award 2Health News:Low-Income Families Often Miss Out on Proper Nutrition 2Health News:Chemical produced in pancreas prevented and reversed diabetes in mice 2Health News:Neuroscientists find famous optical illusion surprisingly potent 2Health News:P7 protein resistance mutations identified; represent drug targets for hepatitis C virus 2Health News:Flexible Schedule Helps Keep New Moms in the Workplace 2
It is available in a 5cc-balloon version with round tip and two opposing eyes, and a 30cc-balloon version with two staggered eyes. BARDEX Silicone-Elastomer Foley Catheters are also available in kits...
All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Intended for one-time use....
The BARDEX I.C. Catheter represents Bard's newest technology in providing protection against NUTI....
Used to provide bladder drainage by percutaneous placement of a Malecot catheter. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: